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ABSTRACT
Objective: The uromodulin, a glycoprotein, expressed and secreted by epithelial kidney cells lining the thick ascending limb of the Henle’s loop. It is 
encoded by the UMOD gene in humans. Our objective was to analyze single nucleotide polymorphisms (SNPs) in the UMOD promoter region in patients 
with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Results: UOMD promoter region polymorphisms using PCR-SSCP and sequencing DNA appeared three different conformational haplotypes, including 
A\G 49 haplotype (5 bands), A\G 49 and C\A 247 haplotype (5 bands), and C\G 45 and A\G 49 haplotype (6 bands) distributed among CKD and ESRD 
cases, due to the presence of three SNPs. There was no association between band numbers of PCR-SSCP with ESRD and CKD compared with a control 
group.
Conclusion: SSCP-PCR is a good screening method to detect genetic variations in an uromodulin promoter region.
Keywords: Chronic kidney disease, End-stage renal disease, UMOD-promoter region, SNPs, Single-strand conformation polymorphism-polymerase 
chain polymorphisms.
INTRODUCTION Inspite of over 50 years of uromodulin analysis that focuses on its 
physiological roles has remained elusive, causing a gradual decline of 
the research. Recently, highlighted heredity investigations that proved 
the importance of this protein, since the uromodulin mutations were 
implicated in dominant tubulointerstitial viscus ill health [2,5]. Several 
genome-wide association studies (GWASs) investigated a lot of UMOD 
genetic risk loci (such as rs12917707, rs6497476, and rs4293393) 
were concerned with estimated glomerular filtration rate (eGFR) 
related to chronic kidney disease (CKD) or upset [6,7]. In 2009, the 
single-nucleotide polymorphisms (SNPs) in the UMOD gene were 
investigated among a big cohort of patients suffering from CKD and 
found that these SNPs may be implicated to the genetic standing in end-
stage renal disease (ESRD) [8]. SNPs are single-nucleotide variations 
that have arisen randomly over time in the human genome, and it is 
mostly occurring in noncoding regions [7,8]. The aim of the study was 
to analyzes single-nucleotide polymorphism (SNP) in the promoter 
region of the UMOD gene in patients suffering from CKD and ESRD 




This was a case study conducted in the Biotechnology and Genetic 
Engineering Laboratory, Department of Biology, College of Science, 
University of Babylon, Iraq. The blood samples (150) were collected 
from patients suffering from CKD (50) and ESRD (50), in addition to 
healthy persons (50) as a control group. Blood samples were taken 
from out-and in-patients who admitted to Merjan Teaching Hospital 
(Dialysis Center), Babylon Province, from February to July 2016. All 
the participants were evaluated by a certified physician, who was also 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i1.22063
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Methods: The blood samples were collected from 100 patients with CKD (50) and ESRD (50), who admitted at Merjan Teaching Hospital in Babylon
 Province, Iraq (February-July 2016). In addition, 50 blood samples of healthy control. The SNPs of UMOD promoter region was investigated 
using single-strand conformation polymorphism-polymerase chain polymorphisms (SSCP-PCR) and DNA sequencing techniques. 
Uromodulin is an integral glycoprotein with the epithelial kidney lining 
cell membrane by glycophosphatidylinositol (GPI)-anchored. It
 is  completely  produced by the thick ascending limb (TAL) of  the 
Henle’s  loop and excreted in  ordinary urine.  In  human,  the 
uromodulin is  encoded by the UMOD  gene,  which composed of  eleven 
exons located on chromosome 16p12.3 [1,2]. The primary structure of
 the polypeptide chain which containing 640 amino acids (aa) with 
a  signal  sequence  (24  aa)  and  8  potential  N-linked 
glycosylation  sites  [3].  Sequence  homology  revealed  that  the 
protein  is  may  contain  N-terminal  signal  sequence;  three 
epidermal growth factor (EGF)-like domains, the second and 
third of EGF-like domains contain a calcium-binding motif; a
 central domain of eight cysteines (D8C) within a cysteine- rich 
region;  a  zona  pellucida  domain  is  essential  for  the  extracellular 
protein  polymerization  into  helical  filaments;  and 
GPI-anchoring  site  for  integrating  the  protein  with  the  cell 
membrane  [4].  A  key  structural  feature  of  the  uromodulin  is  rich 
cysteine  amino  acid  content  (48  cysteines)  for  creating  24  intrachain 
disulfide  bridges,  which critical  to  construct  the  correct  structure [3]. 
The biosynthesis of this protein and modification occurs in the rough
 endoplasmic  reticulum  (RER)  of  the  TAL  cells  of  the  kidney.  The 
protein  precursor  (84  kDa)  is  modified  by  adding  the  carbohydrate 
moiety  and  GPI  anchor-linked  molecule  to  become  mature 
macromolecule  with  a  noticeable  mass  of  97  kDa.  The  mature 
macromolecule once transports across the plasma membrane, cleaved
 and the free parts  secreted with the tubular  fluid [3,4].  The 
uromodulin is existing in urine as a big aggregates or polymeric
 of  glycoprotein,  and  their  molecular  weight  reached  to  millions  of 
Daltons.  The rate-limiting step in the uromodulin maturation is  that  the 
pathway  inside  the  RER,  in  all  probability  as  a  result  of  the 
tertiary structure forming [1].
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responsible for getting the most analytical and clinical values such as 
urea and creatinine concentrations. The patients with hepatitis were 
excluded from the study.
Genotyping using PCR-SSCP technique
The genotyping of the studied groups were performed using the 
SSCP-PCR technique after DNA extraction from blood samples. DNA 
was extracted from blood samples and purified using extraction and 
purification kit (Geneaid company - UK).
The targeted sites of the UMOD promoter regions were 
amplified using design-specific primers (Bioneer, IDTDNA 
- USA). Forward: 5’-GGGGATCTTCTCCCTTGGC-3’; Reverse: 
5’- CAACCCACGTCACAGGGAAG-3’.
PCR was carried out in the reaction mixture containing 1 µl from 
forward and reverse primers, 12.5 µl of Green Master Mix, and 3 µl of 
genomic DNA, and the volume of reaction was completed up to 20 µl by 
adding 2.5 µl of the nuclease-free water. Amplification was carried out 
in a TRIO Thermal Cycler (Biometra, Germany) programed for 2 min 
pre-denaturation at 94°C; 30 cycles, 5 min at 94°C (DNA denaturation), 
1 min at 61°C (annealing), and 1min at 72°C (extended); and a final 
extension of 5 min. PCR products were electrophorezed using gel 
electrophoresis (Cleaver Scientific - UK) in 1% agarose at 75 V for 
1 hand visualized by ethidium bromide. Photos were taken using gel 
documentation system (Cleaver Scientific - UK).
After the amplification of the target sequence, SSCP was performed 
using polyacrylamide gel (PAG) electrophoresis throughout the 
following steps:
1. The 8% PAG was prepared and poured into the medium-casting tray 
(20 × 20 × 0.1 cm; H × W × T). The PAG (total volume 40 ml) composed 
of 8 ml of 40% acrylamide/bisacrylamide, 4 ml of 10× TBE, 2.8 ml of 
glycerol, 40 µl of TEMED, 400 µl of 10% ammonium persulfate, and 
24.8 ml of deionized water.
2.	 During	the	gel	solidified,	the	DNA	samples	were	prepared	by	mixing	
10 µl of PCR products with10 µl of 2× SSCP loading dye in Eppendorf 
tubes separately. Then, they incubated in a water bath at 95°C for 
7 min. Subsequently, the mixtures immediately were placed in an ice 
bath for 5 min.
3. The samples were loaded into 8% PAG and migrated using vertical 
electrophoresis	unite	(Cleaver	Scientific	-	UK)	at	200	V,	35	mA,	and	6	W	
for 180 min or until SSCP tracking dye reaches the bottom of the gel.
4. 4. The gels visualized by ethidium bromide. Photos were taken using 
gel documentation system (EBOXCX - UK).
Sequencing of amplified DNA fragment 
The amplified fragments were purified using the protocol suggested 
by Macrogen sequencing company (Macrogen - Korea), and then, they 
were sequenced using each primer pair. The sequences of the gene 
fragments analyzed were aligned by multiple sequence alignment 
program, according to Bio-edit, with the sequences published in the 
Gen Bank database taken as a reference to identify the polymorphisms.
Statistical analysis
Statistical	analysis	was	carried	out	using	SPSS	version	16,	and	p	≤	0.05	
was considered statistically significant.
RESULTS
The cases of the study involved 150 samples divided into three 
groups: Two patient groups, including chronic and ESRD (each of 
them containing 50 patients) and healthy control groups (50). The 
study included female and male as a percentage 50% for both at the 
age ranged between 11 and 80 years. Furthermore, the percentage of 
hypertension was present in 43.33%, while in non-hypertension group 
was 56.665%. In addition, the percentage of patients with diabetes was 
10%, whereas non-diabetic patients were 90%. Finally, the percentage 
of smoker patients was 33.33%, whereas the nonsmoker patients was 
66.66%.
The results revealed that the CKD and ESRD groups had high significant 
differences	 (p≤0.05)	 of	 urea,	 creatinine,	 and	 calcium	 levels	 in	
comparison with control groups. These levels significantly increased 
(p≤0.05)	 in	 female	 and	 male	 patient	 group	 compared	 with	 control	
groups.
The genomic DNA was extracted from the blood samples and electrically 
migrated in 1% agarose, 75 V, 20 mA for 1h, (Fig. 1). Fig. 2 showed the 
amplification product of the UOMD promoter region. Fig. 3 showed 
PAG electrophoresis of SSCP-PCR conformational haplotypes of the 
amplified products (317 bp) of promoter region of UOMD gene.
The results of UOMD promoter region polymorphisms revealed that 
the presence of four different conformational haplotypes appeared 
in patient and control groups, including haplotype with 4 bands, two 
haplotype patterns (a and b) containing 5 bands and haplotype with 
6 bands. Whereas the sequencing results (Fig. 4) showed the presence 
of three SNPs determined the haplotypes of the UOMD promoter region 
Fig. 1: The electrophoresis pattern of genomic DNA extracted 
from blood of patients with chronic kidney disease and end-stage 
renal disease as well as healthy control groups. Lane 1-20 refers 
to extracted DNA from blood samples; electrophoresis conditions: 
1% agarose, 75 V, 20 mA for 1 h (10 μl in each well).
Fig. 2: Agarose gel electrophoresis of amplified products of UOMD 
promoter region of patients with chronic kidney disease and 
end-stage renal disease and healthy control groups. M: DNA size 
marker; lane 1-11 refers to the patterns of amplified products 
of UMOD promoter region (317 bp). Electrophoresis conditions: 
1% agarose, 75 V, 20 mA for 120 min. The band staining with 
ethidium bromide
Fig. 3: DNA polymorphisms of the UOMD promoter region of 
patients chronic kidney disease (CKD), end-stage renal disease 
(ESRD) and control using polymerase chain polymorphisms-
single-strand conformation polymorphism technique. Lanes 2 
and 9 represent the control group; lanes 1, 3-8, and 10 represent 
the groups of patients (CKD and ESRD). Electrophoresis 
conditions: 8% polyacrylamide, power applied: 200 V-100 mA, for 
180 min. The DNA bands stained using ethidium bromide
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depending on Primer3 plus reference sequences (ID: AY061638.1). 
These SNPs were C\G 45, A\G 49, and C\A 247 that distributed among 
CKD and ESRD patients. According to PCR-SSCP and sequencing results, 
there were three conformational haplotypes appeared among patient 
groups in comparison with control group (4-bands haplotype) (Fig. 5). 
There was A\G 49 conformational haplotype, which appeared 5 bands 
(3-7) in ESRD and CKD cases. The second was A\G 49 and C\A 247 
conformation haplotypes, which showed the presence of 5 bands 
(2, 4-7) distributed in ESRD cases. The third was C\G 45 and A\G 49 
conformational haplotype, which revealed the presence of 6 bands 
(1, 3-7) in ESRD cases. Furthermore, the results showed that there was 
no association between numbers of bands of PCR-SSCP with ESRD and 
CKD that indicates the SNPs were associated with both CKD and ESRD.
Table	 3	 refers	 to	 the	 present	 significant	 differences	 (p≤0.05)	 in	
the serum levels of urea, creatinine, and calcium among PCR-SSCP 
polymorphisms of the UMOD gene in ESRD group, while there are no 
significant differences in the concentrations in CKD group.
DISCUSSION
The consequences of the promoter region of the uromodulin encoding 
gene illustrated that four different haplotypes according to the number 
and location of the bands in the gel. These conformations including 4, 
5 (two types 5a and 5b), and 6 bands. These variable conformations 
(5a, 5b, and 6 bands) may be due to the presence of three SNPs within 
the studied region which determined by the DNA sequencing results, 
whereas the haplotype with 4 bands in patient groups and control was 
not contained the detected SNPs, that may indicate the patient group 
containing other SNPs in other UMOD regions or other related genes 
because of the renal disease is multi-factorial. Conversely, these SNPs 
were detected between two groups of renal disease; in ESRD patient 
Fig. 4: Sequences alignment ID: AY061638.1 results for Homo sapiens, UOMD gene promoter region by Bio Edit program version 7.2.5. 
Samples (1, 5, and 9) refer to control, samples (2, 3, 4, 6, 7, 8, 10, and 11) refer to patients, including end-stage renal disease (2, 3, 8, and 
11 samples) and chronic kidney disease (4, 6, 7, and 10 samples)
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groups, the results indicate that there was no association between 4, 5, 
and 6 bands and CKD as compared with a control group. UMOD gene is 
transcribed utterly within the urinary organ as disclosed by Northern 
blot analysis. The transcription specificity of UMOD is about by its 
promoter sequence. The biological effectiveness of uromodulin is still 
rather mysterious, and it may have ability to conserve water/electrolyte 
balance inside the TAL depending on its gelification and physicochemical 
characteristics. In addition, it has protective effects against urinary tract 
infections (UTI) in Umod knockout mice [9]. This function is due to the 
ability of the uromodulin through its rich-mannose moiety to bind with 
the fimbria of bacteria such as Escherichia coli [10].
GWASs have successfully identified genomic loci comprising 
susceptibility variations related to the risk of complex characters 
and markers of renal function [11]. Particularly, common variants 
in the uromodulin encoding gene have been related to the risk of 
CKD, eGFR, and other complex characters, such as kidney stones 
and hypertension. One of the first GWASs on CKD applied on 20000 
participants of European ancestry from unselected, population-
based groups from the CHARGE association, investigated a high 
SNP (rs12917707) placed 3.4 upstream of uromodulin encoding 
gene [12]. However, the rs12917707 variant of UMOD was related to 
renal function indices which depending on the serum cystatin C and 
Conformational haplotypes ESRD group number (%) Control group number (%) p value OR 95% CI
4 bandsa 18 (36) 23 (46) 0.25 1.47 0.28 - 1.61
5 bands 22 (44) 19 (38)
6 bands 10 (20) 8 (16) 0.29 1.59 0.52 - 4.87
5 bandsa 22 (44) 19 (38) 0.65 1.07 0.35 - 3.28
6 bands 10 (20) 8 (16)
Total number 50 50
aReference;	*p≤0.05;	OR=95%	CI;	ESRD:	End-stage	renal	disease,	PCR-SSCP:	Polymerase	chain	polymorphisms-single-strand	conformation	polymorphism,	OR:	Odds	
ratio, CI: Confidence interval
Conformational haplotypes CKD group number (%) Control group number (%) p value OR 95% CI
4 bandsa 19 (38) 23 (46) 0.50 1.33 0.46-2.61
5 bands 21 (42) 19 (38)
6 bands 10 (20) 8 (16) 0.32 1.51 0.49-4.59
5 bandsa 21 (42) 19 (38) 0.52 1.13 0.37-3.45
6 bands 10 (20) 8 (16)
Total number 50 50
aReference;	*p≤0.05;	OR=95%	CI;	CDK:	Chronic	kidney	disease,	ESRD:	End-stage	renal	disease,	PCR-SSCP:	Polymerase	chain	polymorphisms-single-strand	conformation	
polymorphism, OR: Odds ratio, CI: Confidence interval
Table 3: The association of PCR-SSCP polymorphisms of UOMD gene in renal disease groups with physiological parameter
PCR-SSCP haplotypes band 
number (n)
Mean±SE
Urea (ng/ml) Creatinine (ng/ml) Calcium (ng/ml)
CKD
4	(n=18) 26.45±1.68 511.55±28.64 2.25±0.15
5	(n=22) 25.34±1.78 696.94±43.87 2.23±0.08
6	(n=10) 27.96±1.36 597.49±72.19 2.04±0.14
p value 0.62 0.01 0.55
ESRD
4	(n=19) 26.39±1.82 579.46±40.24 1.89±0.06
5	(n=21) 24.421.20 685.51±40.61 1.87±0.12
6	(n=10) 21.24±2.72 521.19±76.86 1.80±0.06
p value 0.19 0.069 0.84
n: Patient number, CKD: Chronic kidney disease, ESRD: End-stage renal disease, p≤0.05. The results represent as mean±SE (standard error), PCR-SSCP: Polymerase chain 
polymorphisms-single-strand conformation polymorphism
CONCLUSION
SSCP-PCR is a good screening method to detect genetic variations in an 
uromodulin promoter region.
Table 1: PCR-SSCP haplotype distribution of UMOD promoter region by the number of bands and their association with ESRD and control 
groups
Table 2: PCR-SSCP haplotype distribution of UMOD promoter region by the number of bands and their association with CKD and control 
groups
creatinine.  This  variant  related  to  both  higher  eGFRcys  and 
eGFRcreat  and  lower  risk  of  the  developing  CKD.  In  line  with  a 
defensive  result.  As  inevitable,  the  variants  describe  higher  than 
make a case for a tiny, low shear (typically, lower than 1%) of 
the  variation  in  eGFRcrea.  Notably,  there  was  no  significant 
relationship  between  rs12917707  and  hyperuricemia  or  arthritis 
[7].
Depending on the finding of Köttgen [11] which revealed that the SNP
 rs4293393  positioned  at  300bp  upstream  of  the  uromodulin 
encoding gene, is related to increasing a risk of CKD and raised serum 
creatinine (sCreat) in the Icelandic population. The rs4293393 
variation  was  additionally  connected  with  uric  acid  levels 
increasing  and  amplified  risk  of  arthritis,  a  distinction  with  a  lower 
danger of creation of calcium- containing urinary organ stones within 
the Icelandic population. The relationship between the rs4293393 
and rs12917707 variants with creatinine levels increasing was 
definitely  in  a  meta-analysis  of  five  Europeans  isolates 
(EUROSPAN) and at intervals of the large European cluster [12].
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…………318bp 
Control:.......... T G A C A C A[ C ]A CC [A ]A CC T C T C ATT C TATTT AA C A C T [C ]G C TA G C T
G T G TAA
A\G 49:             ...........G ... ....... ... ... .. ..................
A\G 49, C\A 247: ...........G ... ....... ... ... .. ....A .............
C\G 45 & A\G 49: .......G ...G ... ....... ...  ... .. ..................








Fig. 5: Association of PCR-SSCP conformations and DNA-sequences 
of UMOD promoter region in patients with CKD and ESRD. Lane 1: 
Control conformation; 4 bands (3, 4, 5, and 7) of samples 2, 9, and 
5. Lane 2: A\G 49 conformation (a); 5 bands (3, 4, 5, 6, and 7) of 
samples of ESRD (1) and CKD ( 4, 8, and 11). Lane 3: A\G 49 and 
C\A 247 conformation (b); 5 bands (2, 4, 5, 6, and 7) of sample 10 
of ESRD. Lane 4: C\G 45 and A\G 49 conformation; 6 bands (1, 3, 
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